Leveraging the M3 Group’s comprehensive capabilities and collaboration
First written in FY2016-Q4. 5 of 6 entries say "Restated". Latest entry: FY2020.
No other company in this theme has enough history to compare yet.
- FY2020RestatedAnnual report
「Operational cooperation and the establishment of a collaborative framework focused on commercializing a depression biomarker.」
Operational cooperation and collaboration with M3,Inc. are continuing as a means of commercializing the depression biomarker business. - FY2019RestatedAnnual report
「Operational cooperation and the establishment of a collaborative framework focused on commercializing a depression biomarker.」
The collaborative framework with M3,Inc. continues to be positioned as a means of commercializing the business. - FY2017RestatedAnnual report
「We entered into a capital and business alliance agreement with M3,Inc. and conducted a third-party allotment of shares to M3,Inc., 株式会社平田牧場, 株式会社山形銀行 and 株式会社荘内銀行. We subsequently undertook activities to expand the metabolome analysis business and accelerate the practical application and commercialization of depression biomarkers.」
Continuing to leverage collaboration with alliance partners, including M3, to expand the business and accelerate practical application. - FY2017-Q2RestatedAnnual report
「In addition, using the combined capabilities of M3,Inc. and its group companies, our capital and business alliance partner, we undertook promotional activities and other initiatives aimed at disseminating depression biomarkers, as well as identifying partner medical institutions and undertaking other initiatives toward full-scale clinical development.」
Continuing promotional activities by leveraging the combined capabilities of M3 and its group companies. - FY2017-Q1RestatedAnnual report
「In addition, using the combined capabilities of M3, our capital and business alliance partner, and its group companies, we undertook promotional activities and other initiatives aimed at disseminating depression biomarkers.」
Continuing promotional activities by leveraging the combined capabilities of the M3 group and collaboration with it. - FY2016-Q4First statedAnnual report
「Following the execution of the capital and business alliance agreement with M3, we will further accelerate the practical application and commercialization of depression biomarkers by leveraging the combined capabilities of its group and strengthening collaboration.」
Shows the use of the alliance partner group’s combined capabilities and strengthened collaboration as means of accelerating commercialization.